BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33213275)

  • 1. Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20.
    Al-Sharaky DR; Abdelwahed M; Asaad N; Foda A; Abdou AG
    J Immunoassay Immunochem; 2021 May; 42(3):236-251. PubMed ID: 33213275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
    Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
    Jung M; Kim B; Moon KC
    Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
    Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
    Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
    Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
    PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
    Bontoux C; Rialland T; Cussenot O; Compérat E
    Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis.
    Gil da Costa RM; Oliveira PA; Vasconcelos-Nóbrega C; Arantes-Rodrigues R; Pinto-Leite R; Colaço AA; de la Cruz LF; Lopes C
    Int J Exp Pathol; 2015 Oct; 96(5):319-25. PubMed ID: 26515584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
    Serag Eldien MM; Abdou AG; Elghrabawy GRA; Alhanafy AM; Mahmoud SF
    J Immunoassay Immunochem; 2021 Nov; 42(6):662-678. PubMed ID: 34106817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
    Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
    Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma.
    Kim B; Jang I; Kim K; Jung M; Lee C; Park JH; Kim YA; Moon KC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.
    Edgecombe A; Nguyen BN; Djordjevic B; Belanger EC; Mai KT
    Appl Immunohistochem Mol Morphol; 2012 May; 20(3):264-71. PubMed ID: 22498670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.
    Bejrananda T; Kanjanapradit K; Saetang J; Sangkhathat S
    Sci Rep; 2021 Oct; 11(1):21186. PubMed ID: 34707176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
    Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
    Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
    Kim JM; Choi E; Sung SH; Kang H; Park S
    Pathol Res Pract; 2023 Nov; 251():154839. PubMed ID: 37801908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of basal cytokeratin expression in breast cancer.
    Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
    Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
    Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
    J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
    Iakymenko OA; Briski LM; Delma KS; Jorda M; Kryvenko ON
    Am J Surg Pathol; 2022 Apr; 46(4):454-463. PubMed ID: 34560681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
    Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
    Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study.
    Hemida AS; Aiad HAES; Hassan NA; Al Sharaky DR
    J Immunoassay Immunochem; 2022 Nov; 43(6):618-633. PubMed ID: 35787739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis.
    Hashmi AA; Hussain ZF; Irfan M; Edhi MM; Kanwal S; Faridi N; Khan A
    BMC Res Notes; 2018 Mar; 11(1):207. PubMed ID: 29587848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.